4/A: ImmuCell CEO Amends Insider Stock Purchases

ImmuCell's President and CEO, Paul te Boekhorst, filed an amended Form 4 to correct details of recent common stock purchases, increasing his direct beneficial ownership to 9,738 shares.

Summary

• Paul Francis Olivier te Boekhorst, President and CEO of ImmuCell Corp, filed an amended Form 4 (Form 4/A) to correct previously reported transaction details.
• The amendment clarified two common stock purchase transactions made by the CEO.
• On December 3, 2025, 3,598 shares of common stock were purchased at a price of $5.045 per share, resulting in a direct beneficial ownership of 7,306 shares after this transaction.
• On December 4, 2025, an additional 2,432 shares of common stock were purchased at a price of $5.5002 per share, bringing the total direct beneficial ownership to 9,738 shares.
• The amendment specifically corrected the amount and price for the December 3rd transaction and the amount, price, and transaction date for the December 4th transaction.

Sentiment

Score: 7

Explanation: The filing indicates insider buying by the CEO, which is generally a positive signal of confidence in the company's future, despite the minor administrative error requiring an amendment.

Positives

• The President and CEO, Paul te Boekhorst, increased his direct beneficial ownership in ImmuCell Corp by a total of 6,030 shares (3,598 + 2,432).
• This insider buying activity, even with a correction, generally signals management's confidence in the company's future prospects and valuation.
• The CEO's total direct beneficial ownership now stands at 9,738 shares, aligning his interests further with shareholders.

Negatives

• The necessity of filing an amendment indicates an initial error in reporting the transaction details, which could suggest minor administrative oversight.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This filing, detailing insider stock purchases, is specific to ImmuCell Corp and does not provide broader industry context or trends. Insider buying can sometimes be a positive signal within the biotechnology or animal health sector, indicating confidence in future product development or market penetration.

Related Party Transactions

• The filing details insider stock purchases by the CEO, which are a form of related party transaction, specifically the acquisition of 3,598 shares on 12/03/2025 and 2,432 shares on 12/04/2025.

Stakeholder Impact

• Shareholders: May view the CEO's increased stake as a positive sign of confidence in the company's prospects, potentially boosting investor sentiment.
• Employees: No direct impact is mentioned, but a confident CEO could indirectly foster a positive work environment.
• Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Recommendation

While the insider buying by the CEO is a positive signal, a Form 4/A filing primarily reports a transaction correction and does not provide sufficient fundamental or strategic information to warrant a 'buy' or 'strong buy' recommendation. It reinforces confidence but doesn't introduce new growth drivers or financial performance data. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive sentiment without overstating its immediate impact on the company's long-term investment thesis.

Keywords

ImmuCell, ICCC, Form 4/A, insider trading, stock purchase, CEO, beneficial ownership, Paul te Boekhorst, amendment, equity